You are here: Industry Insights > Everest Medicines

News List

Everest Medicines Announces Strategic Commercial Partnership with Global Technology Company, Tencent prnasia
July 12, 2021
Everest Medicines announced that it has entered into a strategic commercial partnership with Tencent, one of the world's largest technology companies, to explore novel ways to optimize meaningful digital engagement with patients and healthcare providers.
Everest Medicines Announces China NMPA Has Granted Priority Review for Sacituzumab Govitecan-hziy in Metastatic Triple-Negative Breast Cancer prnasia
May 21, 2021
Everest Medicines announced that sacituzumab govitecan-hziy (SG) was granted Priority Review by the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA).
Everest Medicines Receives Orphan Drug Designation from the Ministry of Food and Drug Safety in South Korea for Sacituzumab Govitecan-Hziy in Metastatic Triple-Negative Breast Cancer prnasia
May 06, 2021
Everest Medicines, a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products in Greater China and other parts of Asia, announced today that the Ministry of Food and Drug Safety (MFDS) in South Korea ...
Everest Medicines Announces Selection as a Constituent of Certain Indexes of Hang Seng Indexes Company Limited prnasia
March 01, 2021
Everest Medicines, a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products that address critical unmet medical needs for patients in Greater China and other parts of Asia, today announced that the ...
Everest Medicines Initiates Submission of New Drug Application in Singapore for Sacituzumab Govitecan-Hziy for the Treatment of Metastatic Triple-Negative Breast Cancer prnasia
January 07, 2021
Everest Medicines, a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products that address critical unmet medical needs for patients in Greater China and other parts of Asia, announced that it has ...
Everest Medicines Announces CTA Approval by China NMPA for Phase 3 Trial of Sacituzumab Govitecan-Hziy for Metastatic Urothelial Cancer prnasia
January 07, 2021
Everest Medicines, a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products that address critical unmet medical needs for patients in Greater China and other parts of Asia, announced that the Center ...
First Patient Dosed in Phase 3 Registration Asian Study of Trodelvy for Breast Cancer americanpharmaceuticalreview
December 30, 2020
Everest Medicines announced the first patient has been dosed in the Phase 3 registration Asian study EVER-132-002 evaluating TrodelvyTM (sacituzumab govitecan) versus treatment of physician’s choice (TPC) in subjects with hormonal ...
First Patient Dosed in Trodelvy Trial for Metastatic Triple-Negative Breast Cancer americanpharmaceuticalreview
November 12, 2020
Everest Medicines announced the first patient has been dosed in China into the EVER-132-001 Phase 2b registration clinical trial evaluating Trodelvy (sacituzumab govitecan, IMMU-132) for the treatment of patients with metastatic triple-negative ...
Calliditas Therapeutics signs agreement with Everest Medicines to develop and commercialize Nefecon biospectrumasia
June 10, 2019
Calliditas Therapeutics AB (“Calliditas”) and Everest Medicines II Limited (“Everest Medicines”) announced that they have entered into a license agreement to develop and commercialize Calliditas’ leading drug candidate Nefecon in Greater China and Singapo
Everest Medicines acquires rights to Novartis liver cancer treatment biospectrumasia
June 28, 2018
FGF401 is being evaluated in Phase I/II clinical trials across the U.S., Europe and Asia as a potential new treatment for hepatocellular carcinoma.

Previous page 1 2 Next page